Tumor ablation after chemo for advanced pancreatic cancer
Part of Cancer, Digestive system clinical trials.
This study tests a procedure called irreversible electroporation (IRE), which uses electric pulses to destroy cancer cells, after chemotherapy for advanced pancreatic cancer that hasn't spread. It aims to control the tumor and improve outcomes in people who are not eligible for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have pancreatic cancer that has not spread to other organs.
- You have already completed at least 3 rounds of chemotherapy without the cancer getting worse.
- You have a tumor that touches major blood vessels, making it not removable by surgery.
- You are generally in good health with adequate blood counts and organ function.
- You have not had other cancer treatments in the past 6 months, except prior chemo for early-stage disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new procedure called IRE (a way to destroy tumors) for people with liver cancer that has not responded well to initial immunotherapy. It aims to help when surgery is not possible due to the tumor's size or location.
This trial is testing a new treatment called HCA nano for a type of bile duct cancer that cannot be removed by surgery and has not spread. It is for patients whose cancer did not grow after standard chemotherapy.
This study looks at people with advanced pancreatic cancer who have already been treated with a procedure called irreversible electroporation (IRE), which uses electric pulses to kill cancer cells, sometimes along with immunotherapy drugs. The goal is to learn more about how well this combination works and how safe it is.
This early study tests a combination of chemotherapy and a procedure called irreversible electroporation (IRE) for people with stage III pancreatic cancer. It may help shrink or control tumors, and also studies safety in this group.
This trial tests a new combination: a special electric field treatment (IRE) plus a dual-function antibody (PD-1/CTLA-4) for people with locally advanced pancreatic cancer that didn't respond to standard chemotherapy. The goal is to see if this approach can help shrink or control the cancer.
This trial tests a new drug called mitazalimab injected directly into the tumor, combined with a special electrical procedure that kills cancer cells. It is for people whose pancreatic cancer has not spread but cannot be removed by surgery.
Hear when a new IRE trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.